An Exploratory Study of Sunitinib (SU) Plus Docetaxel (D) and Trastuzumab (T) for First-Line Therapy of HER2+Advanced Breast Cancer (ABC).
- Resource Type
- Journal
- Source
CANCER RESEARCH ; DEC 15 2009, 69 24, p852S-p853S, 2p. Supplement: 3- Subject
- Language
- English
- ISSN
- 00085472